China agrees to start clinical trials for the third anti-corona vaccine from "Sinopharma"

Sinopharma announced that Beijing has agreed to start clinical trials of the company's third anti-virus vaccine.

And the green light to start trials comes after two inactive vaccines were approved by Sinopharma, which have been widely used at home and in developing countries, according to Bloomberg News.

The third vaccine is a reconstituted vaccine, and it includes parts of the spike protein (Spike) to stimulate the immune response, according to a statement published on the company's official page on the WeChat website today, Saturday.

Follow our latest local and sports news, and the latest political and economic developments via Google news